Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07063316

SGLT2 Inhibitors and Renal Anemia in Japan: RWD

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The objectives of the study are: 1. To evaluate the association between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor use and the occurrence of anemia in patients with chronic kidney disease (CKD) using a nested case-control design with incidence density sampling. 2. To evaluate anemia-related outcomes using a nested case-control-based analytical framework, including assessment of within-subject changes in anemia-related treatments and healthcare costs by comparing the period after study entry with the period after the index date (for cases) or matched reference date (for controls), and comparison according to SGLT2 inhibitor use: A) Prescription patterns and treatment regimens for anemia, including analysis of medication types, dosing strategies, and duration of treatments B) Anemia-related healthcare costs C) Change in laboratory values

Official title: Effect of SGLT2 Inhibitors on Renal Anemia and Its Management in Patients With CKD in Japan

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

15000

Start Date

2025-07-23

Completion Date

2026-12-25

Last Updated

2026-05-08

Healthy Volunteers

No

Interventions

DRUG

SGLT2 inhibitor

SGLT2 inhibitor

Locations (1)

Nippon Boehringer Ingelheim Co ., Ltd.

Tokyo, Japan